Key points from article :
Underdog Pharmaceuticals has been awarded an Innovation Passport under the UK’s Innovative Licensing and Access Pathway (ILAP).
It is on a mission – not to treat age-related diseases, but to tackle the causes using simple and direct interventions.
By targeting oxidised cholesterol, it aims for the first true disease-modifying treatment for atherosclerosis, heart attack & stroke.
Products are based on novel derivatives of a well-known, safe compound.
Custom-engineered cyclodextrins tackle cholesterol derivatives such as 7-ketocholesterol.
UDP-003 is designed to target and remove toxic oxidised cholesterol, a key driver of arterial plaque accumulation.
Underdog is one of the first companies, and UDP-003 one of the very few pre-clinical therapies, to receive an ILAP designation.
“There is an enormous public need for drugs which can significantly reverse atherosclerosis, rather than manage or delay its onset,” - Matthew O’Connor, Underdog CEO of Scientific Affairs.
